Diagnostic Center | June 26, 2024
Imfinzi improved event-free survival and overall survival for bladder cancer
First immunotherapy regimen before and after surgery to extend survival in bladder cancer
First immunotherapy regimen before and after surgery to extend survival in bladder cancer
Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
Merck shared updates on the company’s oncology pipeline and focused R&D approach
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
The award recognizes powerful science–industry collaborations for social good
The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
Subscribe To Our Newsletter & Stay Updated
